Your browser doesn't support javascript.
loading
Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre's Real-World Experience.
Du, Yue Jennifer; Fu, Rui; Levinsky, Justin T; Kamalraj, Pabiththa; Chan, Kelvin K W; Parmar, Ambica; Eskander, Antoine; Smoragiewicz, Martin.
Afiliación
  • Du YJ; Temerty School of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Fu R; Department of Otolaryngology-Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • Levinsky JT; Department of Otolaryngology-Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • Kamalraj P; Department of Otolaryngology-Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • Chan KKW; Department of Otolaryngology-Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • Parmar A; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • Eskander A; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • Smoragiewicz M; Department of Otolaryngology-Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
Curr Oncol ; 30(10): 8928-8935, 2023 09 29.
Article en En | MEDLINE | ID: mdl-37887545
Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world setting. A retrospective chart review was performed on patients who received nivolumab for R/M HNSCC from 2017 to 2020 at a high-volume cancer centre. Data were abstracted from 34 patients, based on physician notes and imaging reports. The median patient age at nivolumab initiation was 61, 24% were female, and 62% were current or former smokers. Prior to nivolumab, 44% of patients underwent surgery, 97% radiation, and 100% chemotherapy. Most (97%) therapies were for primary disease. Overall survival at 6 and 12 months following drug initiation was 38% and 23%, respectively. Progression-free survival at 6 and 12 months was 33% and 22%, respectively. Eighteen percent of patients experienced an immune-related adverse event, the most common of which was pneumonitis (3/8) and endocrine events (3/8). Seven out of eight of the immune adverse events were grade 1-2; 1/8 was grade 3. Nivolumab appears to have decreased survival rates in our single-centre Canadian population compared to CHECKMATE-141 and presented a manageable adverse event profile for R/M HNSCC.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nivolumab / Neoplasias de Cabeza y Cuello Límite: Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Curr Oncol Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nivolumab / Neoplasias de Cabeza y Cuello Límite: Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Curr Oncol Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza